TandemAI Announces the Release of TandemViz™ 1.0 Web-based Graphical User Interface for Seamless Integration of Computational Analyses and Experimental Data

Mar. 28, 2023

Platform Optimizes Data Use to Enhance and Accelerate Clients’ Drug Discovery


TandemAI today announced the release of TandemViz™1.0, the company’s proprietary web-based platform that provides its growing roster of drug discovery clients with a user-friendly and collaborative graphical interface to TandemAI’s suite of computational tools. The platform, which can be accessed from anywhere through a web browser without the need to install any software locally, allows the seamless integration and visualization of experimental data alongside computational analyses.  

“TandemViz™ is central to our approach to integrating advanced computational tools with wet lab technologies,” said Albert Pan, Ph.D., TandemAI’s Chief Technology Officer. “The platform is built to offer access to our free energy perturbation (FEP) workflow, a powerful approach for dramatically speeding up the hit-to-lead and lead optimization stages of drug discovery. As someone who has used FEP and computation to drive multiple drug discovery projects, the TandemViz™ interface is a game changer in enabling the optimal use of computational and experimental data, including atomic-level simulation data, to understand trends and design better molecules.”

The company’s workflow includes modules for protein-small molecule pose generation, accurate derivation of small molecule force field parameters from quantum mechanics, and calculation of small molecule potency using FEP. The platform also makes it easy to derive dynamic molecular rationales for why some compounds are more potent than others through a powerful data analysis interface that combines computational and experimental data organized intelligently as part of project datasets. The proprietary FEP workflow has been thoroughly validated through multiple benchmark datasets and client projects, achieving an average accuracy of 1 kcal/mol mean unsigned error or less relative to experiment. Additional features, including tools for generative design and billion-level virtual high throughput screening, will be available soon in future versions of TandemViz™.

“The Viz interface, with integrated force field reparameterization and detailed simulation visualization, has been instrumental in providing computational insights into how well small molecules are binding to our targets,” said Yax Sun, Ph.D., Co-Founder and Chief Technology Officer of QuantX Biosciences, who has experimented with TandemViz™ as part of TandemAI’s integrated computations-wet lab platform. “These insights have really helped focus our initial medicinal chemistry designs.” Yax was previously at Amgen for over 20 years, most recently as the Head of Computational Chemistry.

Established in late 2021, TandemAI currently has more than 50 clients globally for whom it provides drug discovery services, including advanced computational tools, and access to high performance computing infrastructure that are integrated with in-house wet lab operations. The company has 150 scientists working at its wet lab facilities in Shanghai and Suzhou, China, and recently raised $35 million in a Series A financing to expand its operations.

About TandemAI

TandemAI is an advanced technology company dedicated to reinventing drug discovery infrastructure. The company integrates a proprietary suite of computational tools with its efficient, large-scale in-house wet lab operations to deliver turnkey drug discovery solutions. TandemAI, with offices in New York, Boston, San Diego, and China, has built its networked platform from the ground up in China to increase the speed of drug discovery and deliver cost-effective opportunities to its partners and to the global scientific community. Learn more at www.tandemai.com.


Jinglin Huang, PhD

Chief of Staff

[email protected]

Business Development

[email protected]